[1] Mannelli G, Arcuri F, Agostini T, et al. Classification of tongue cancer resection and treatment algorithm[J]. Journal of Surgical Oncology, 2018,117(5):1092-1099.
[2] Sarah, Djebali, Carrie, et al. Landscape of transcription in human cells[J]. Nature, 2012,489:101-108.
[3] Jun, Wang, Xuan, et al. Regulatory roles of long noncoding RNAs implicated in cancer hallmarks. [J]. International Journal of Cancer, 2019.
[4] Gupta R A, Shah N, Wang K C, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis[J]. Nature, 2010,464(7291):1071-1076.
[5] Zhang S, Ma H, Zhang D, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling[J]. Cell Death Dis, 2018,9(7):742.
[6] Fang Z, Zhang S, Wang Y, et al. Long non-coding RNA MALAT-1 modulates metastatic potential of tongue squamous cell carcinomas partially through the regulation of small proline rich proteins[J]. BMC Cancer, 2016,16:706.
[7] Zhang H, Zhao L, Wang Y X, et al. Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma[J]. Tumour Biol, 2015,36(11):8805-8809.
[8] Jia B, Xie T, Qiu X, et al. Long noncoding RNA FALEC inhibits proliferation and metastasis of tongue squamous cell carcinoma by epigenetically silencing ECM1 through EZH2[J]. Aging (Albany NY), 2019,11(14):4990-5007.
[9] Liu X, Zhang B, Jia Y, et al. SNHG17 enhances the malignant characteristics of tongue squamous cell carcinoma by acting as a competing endogenous RNA on microRNA-876 and thereby increasing specificity protein 1 expression[J]. Cell Cycle, 2020,19(6):711-725.
[10] Shao T, Huang J, Zheng Z, et al. SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma[J]. Cellular Physiology & Biochemistry, 2018,47:26-38.
[11] GZ H, QQ W, ZN Z, et al. Identification of Candidate Biomarkers and Analysis of Prognostic Values in Oral Squamous Cell Carcinoma. [J]. Frontiers in oncology, 2019,9:1054.
[12] Fu Y, Dominissini D, Rechavi G, et al. Gene expression regulation mediated through reversible m(6)A RNA methylation[J]. Nat Rev Genet, 2014,15(5):293-306.
[13] Stower, Hannah. Transcriptome-wide N6-methyladenosine analysis[J]. Nature Reviews Genetics, 2012,13(7):452.
[14] Li S, Mason C E. The pivotal regulatory landscape of RNA modifications[J]. Annu Rev Genomics Hum Genet, 2014,15:127-150.
[15] Schwartz S, Mumbach M R, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites[J]. Cell Rep, 2014,8(1):284-296.
[16] Lin S, Choe J, Du P, et al. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells[J]. Mol Cell, 2016,62(3):335-345.
[17] Zheng G, Dahl J A, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell, 2013,49(1):18-29.
[18] Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST[J]. Mol Cancer, 2020,19(1):46.
[19] Zhou C, Molinie B, Daneshvar K, et al. Genome-Wide Maps of m6A circRNAs Identify Widespread and Cell-Type-Specific Methylation Patterns that Are Distinct from mRNAs[J]. Cell Rep, 2017,20(9):2262-2276.
[20] Zhu S, Wang J Z, Chen, et al. An oncopeptide regulates m(6)A recognition by the m(6)A reader IGF2BP1 and tumorigenesis[J]. Nat Commun, 2020,11(1):1685.
[21] Lun A T, Chen Y, Smyth G K. It's DE-licious: A Recipe for Differential Expression Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR[J]. Methods Mol Biol, 2016,1418:391-416.
[22] Xiao H, He W, Chen P, et al. Identification of Seven Aberrantly Methylated and Expressed Genes in Adrenocortical Carcinoma[J]. Front Endocrinol (Lausanne), 2019,10:472.
[23] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017,45(W1): W98-W102.
[24] Yu G, Wang L G, Han Y, et al. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters[J]. Omics A Journal of Integrative Biology, 2012,16(5):284-287.
[25] Bader G D, Hogue C W. An automated method for finding molecular complexes in large protein interaction networks[J]. BMC Bioinformatics, 2003,4:2.
[26] Amelio I, Cutruzzola F, Antonov A, et al. Serine and glycine metabolism in cancer[J]. Trends Biochem Sci, 2014,39(4):191-198.
[27] Zeidan B, Manousopoulou A, Garay-Baquero D J, et al. Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study[J]. Breast Cancer Res, 2018,20(1):19.
[28] Fridley B L, Ghosh T M, Wang A, et al. Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence[J]. Front Genet, 2016,7:37.
[29] Nagy R, Boutin T S, Marten J, et al. Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 Generation Scotland participants[J]. Genome Med, 2017,9(1):23.
[30] Zeng J H, Liang L, He R Q, et al. Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma[J]. Oncotarget, 2017,8(10):16811-16828.
[31] Shi X, Tan H, Le X, et al. An expression signature model to predict lung adenocarcinoma-specific survival[J]. Cancer Manag Res, 2018,10:3717-3732.
[32] Guan C, Ouyang D, Qiao Y, et al. CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients[J]. J Cell Mol Med, 2020,24(10):5832-5841.
[33] Chien M H, Yang J S, Chu Y H, et al. Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan[J]. PLoS One, 2012,7(12): e51051.
[34] Zapata L, Pich O, Serrano L, et al. Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome[J]. Genome Biol, 2018,19(1):67.
[35] Wahid B, Bashir H, Bilal M, et al. Developing a deeper insight into reproductive biomarkers[J]. Clin Exp Reprod Med, 2017,44(4):159-170.
[36] Zhao B S, Roundtree I A, He C. Post-transcriptional gene regulation by mRNA modifications[J]. Nat Rev Mol Cell Biol, 2017,18(1):31-42.
[37] Roundtree I A, Evans M E, Pan T, et al. Dynamic RNA Modifications in Gene Expression Regulation[J]. Cell, 2017,169(7):1187-1200.
[38] Zhang S, Zhao B S, Zhou A, et al. m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program[J]. Cancer Cell, 2017,31(4):591-606.
[39] Li Z, Weng H, Su R, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase[J]. Cancer Cell, 2017,31(1):127-141.
[40] Zuo X, Chen Z, Gao W, et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma[J]. J Hematol Oncol, 2020,13(1):5.
[41] Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST[J]. Mol Cancer, 2020,19(1):46.
[42] Zhu S, Wang J Z, Chen, et al. An oncopeptide regulates m(6)A recognition by the m(6)A reader IGF2BP1 and tumorigenesis[J]. Nat Commun, 2020,11(1):1685.
[43] Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3[J]. Mol Cancer, 2019,18(1):143.
[44] Wu Y, Yang X, Chen Z, et al. m(6)A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1[J]. Mol Cancer, 2019,18(1):87.